- Home
- GOSS vs ARCT Comparison
GOSS vs ARCT Comparison
Compare GOSS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ARCT
- Stock Information
- Founded
- GOSS 2015
- ARCT 2013
- Country
- GOSS United States
- ARCT United States
- Employees
- GOSS N/A
- ARCT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- ARCT Health Care
- Exchange
- GOSS Nasdaq
- ARCT Nasdaq
- Market Cap
- GOSS 347.8M
- ARCT 373.7M
- IPO Year
- GOSS 2019
- ARCT N/A
- Fundamental
- Price
- GOSS $1.84
- ARCT $14.94
- Analyst Decision
- GOSS Strong Buy
- ARCT Strong Buy
- Analyst Count
- GOSS 4
- ARCT 8
- Target Price
- GOSS $8.25
- ARCT $52.83
- AVG Volume (30 Days)
- GOSS 3.6M
- ARCT 443.2K
- Earning Date
- GOSS 08-11-2025
- ARCT 08-04-2025
- Dividend Yield
- GOSS N/A
- ARCT N/A
- EPS Growth
- GOSS N/A
- ARCT N/A
- EPS
- GOSS N/A
- ARCT N/A
- Revenue
- GOSS $124,590,000.00
- ARCT $143,680,000.00
- Revenue This Year
- GOSS N/A
- ARCT N/A
- Revenue Next Year
- GOSS $65.50
- ARCT $34.08
- P/E Ratio
- GOSS N/A
- ARCT N/A
- Revenue Growth
- GOSS N/A
- ARCT 15.38
- 52 Week Low
- GOSS $0.66
- ARCT $8.04
- 52 Week High
- GOSS $1.94
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- GOSS 70.54
- ARCT 60.54
- Support Level
- GOSS $1.67
- ARCT $12.75
- Resistance Level
- GOSS $1.94
- ARCT $15.83
- Average True Range (ATR)
- GOSS 0.14
- ARCT 0.86
- MACD
- GOSS 0.04
- ARCT 0.12
- Stochastic Oscillator
- GOSS 86.81
- ARCT 71.10
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.